Opendata, web and dolomites


The first effective remedy for acute pancreatitis disease

Total Cost €


EC-Contrib. €






 RAPID project word cloud

Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.

time    optimal    orientale    last    ap    disease    regulatory    preclinical    cellular    pave    validate    indications    tech    care    endoscopic    ema    diseases    innovation    undergo    market    breakthrough    costing    initiation    phases    myopathy    acute    globally    finance    generating    revenues    small    frequent    overload    chemicare    dossier    prior    surgical    2024    reinvested    ready    store    spin    pharma    rare    prepare    preclinically    diagnosis    national    million    hyper    calcium    dystrophy    paths    fda    gastroenterology    utmost    yearly    patients    admitted    emergency    orphan    university    solution    pancreatitis    patented    services    off    visits    operated    cluster    solutions    trials    candidate    activation    aggregate    capacity    piemonte    rapid    trigger    tubular    people    health    proved    ions    advantage    therapeutic    molecules    company    position    entry    discharge    intensive    39    accelerated    therapies    modulate    hospitalizations    healthcare    data    complete    plan    providers    drug    clinical    designation    license    duchenne    muscular    frame    pharmacological    room    burden    validation   

Project "RAPID" data sheet

The following table provides information about the project.


Organization address
address: VIA AMICO CANOBIO 4/6
city: NOVARA
postcode: 28100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHEMICARE SARL IT (NOVARA) coordinator 50˙000.00


 Project objective

ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)


Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More  


Flame Detector Based on Epitaxial Metal Oxides (EMO) Technology

Read More